February 2012.

Contact: Pilar Guerrero/Julio Muoz press@bionaturis.com

Tel. (+34) 910070017/(+34) 616096623

Opening Bell Bionaturis

The Andalusian biotechnology company joins MAB-EE
y y y Bionaturis expects to increase 5 times its sales by 2015 after ending its last four financial years with benefits. Biotechnology is an interesting business for the investors because of its high growth rate. Chairman Juan Jose Almagro and CEO Victor Infante have rung the opening bell.

February 2012. Bionaturis, a biotechnological company which develops and manufactures biological products for human and veterinarian uses, has joined the Spanish Alternative Investment Market. This makes Bionaturis the 18th company to quote in this market. Chairman, Juan Jose Almagro, and CEO, Victor Infante, have rung the traditional opening bell at 12.00 on the 26th January at the Stock Market of Madrid. Bionaturis has reach an investment of 2 million and an IPO of 225 for each stock. Bionaturis ended the 2010 financial year with 553.000 benefit, which means an increase of more than 75% regarding the year before. The companys incomings increased 22% (996.000). Bionaturis expects to increase even 5 times its sales by 2015 after having kept a positive EBITDA since its birth. In words of its chairman, Juan Jose Almagro, Bionaturis has made a perfect combination of development studies, innovation, talent and compromise. Those are aspects that society demands to companies and institutions. Thats why we offer a different way of working and our researches try to bring hope to patients who really need it. Were going to become a reference for the new developers in pharmaceutical industry adds Victor Infante, We expect a 40% growth rate in the next five years. KPMG Works as a consultant, legal advising and law firm, and Bankia works as a cash-flow provider and placement agent.

About Bionaturis Bionaturis is a biopharmaceutical company developing and producing biomedical products for the pharmaceutical and veterinarian sectors. Bionaturis specializes in the prevention and treatment of niche diseases, such as orphan diseases. As value proposition Bionaturis has chosen Nature as an optimized source for the production of biopharmaceuticals, substituting the traditional industrial cumbersome steel reactors for single use, disposable and naturally occurring individual reactors: FLYLIFE. FLYLIFE makes use of natural resources to achieve and indeed surpass the productive capacity of traditional industry standards but utilizing up to ten-fold less space and fifteen-fold less investment. Amongst others, in niche markets where currently there is no solution, these competitive advantages provide a profitable solution and give renewed hope to millions of worldwide patients. Bionaturis staff is highly qualified and multidisciplinary and combine technical capacity with certified experience in the business sector. Both the Board of Directors and the Management Team are a guarantee of business success. Year after year Bionaturis has increased the portfolio of international patents, either developed internally or acquired through license.

For more info: Pilar Guerrero/Julio Muoz eMail: press@bionaturis.com Phone Number: (+34) 910070017/ (+34) 616096623